Proteomics and transcriptomics represent two powerful branches of omics science, offering unique perspectives on gene expression, protein function, and cellular processes. Proteomics focuses on the study of proteins and transcriptomics examines the expression levels of genes through RNA transcripts. Integrating data from these omics disciplines helps to increase the power of data because of how these data complement each other. In this blog, we discuss the power of integrating proteomics and transcriptomics data, the challenges in integrating them across data dimensions and how these challenges might be met by innovative solutions.
Combining proteomics and transcriptomics data has made significant contributions to the understanding of diverse biological pathways in health and disease. These analyses along with other omics approaches provide a more complete picture of disease-related changes to tissue, the contributions of different genes to early stages of disease, and more.
Systems biology uses integrated proteomics and transcriptomics to understand organ function. Comparing mRNA and protein profiles from different cell types in organ tissue enables deeper understanding of the cellular organization of organs. When these different data types are integrated, downstream analyses like cell clustering, gene set enrichment comparisons, cell-cell correlations can be performed. These analyses guide the identification of cell-specific biological processes and aid the discovery of cell-type signatures in case of disease.
In clinical settings, integration of proteomics and transcriptomics makes it possible to compare the profiles of proteins and expressed genes in normal and diseased cells such as tumor tissue. These analyses lend themselves to insights in prognosis, diagnoses as well as prediction. Early detection or prediction of activation of tumor tissue by different growth factors can make crucial differences in treatment and survival rates. In colorectal cancer, the mutations of certain genes can predict resistance to treatment.
Proteome patterns of immune cell types combined with bulk RNA sequencing of those cells can reveal the network of cell-type-specific interactions between cells. This level of analysis is particularly useful to understand immunological responses to infection. It also allows the comparison of immune function across organs or populations. Immune cells can be tissue-resident or recruited into the organ, and distinguishing these origins lends insight into immune function.
Integrating proteomics and transcriptomics data poses several challenges due to the inherent complexities and heterogeneity of biological datasets, the different techniques used in acquiring the data, as well as the levels of data curation in public and private data repositories.
Polly emerges as a transformative solution for mitigating challenges in integrating proteomics and transcriptomics data. By harnessing Polly's advanced capabilities, researchers can seamlessly retrieve and curate data from public and proprietary sources, ensuring access to a comprehensive and diverse collection of omics datasets.
Polly reduces costs and runtimes for data pre-processing, handling and analysis.
By leveraging Polly's integrated omics data platform, researchers can unlock new insights into complex biological processes, accelerating discoveries and advancing scientific knowledge. From elucidating disease mechanisms to identifying therapeutic targets and biomarkers, integrated proteomics and transcriptomics data pave the way for groundbreaking discoveries with profound implications for human health and disease.
Polly is a pioneer in accelerating research timelines and making data integration a priority. From eliminating redundant efforts to fostering collaborative analysis and facilitating breakthroughs in diagnostics and therapeutics, Polly addresses data needs at every step of your research.
Join the community of researchers who have embraced Polly for data harmonization and integration.
Connect with us or reach out to us at info@elucidata.io to learn more.